A woman holds a small bottle labeled with a"Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020.it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government’s vaccine rollouts told Reuters.
Gaithersburg, Maryland-based Novavax, which had never launched a product, had ambitions to provide a vaccine for the world, promising to deliver its shots by mid-2021. Novavax did not provide a timeline but told Reuters it expects to deliver around 80 million doses in the current quarter to COVAX, less than 10%.
Novavax is expected to earn around $5 billion in 2022 from COVID-19 vaccine sales, according to Refinitiv data. At least two EU countries have pushed back their planned timelines for administering Novavax shots as a result, a person familiar with the matter said. “We expect to ship as soon as the testing and release is complete and we are working to make that happen as quickly as possible,” the Novavax spokesperson said.